Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

28.30 +0.93 (+3.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
From Beam Therapeutics
Via GlobeNewswire
Where Beam Therapeutics Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
From Beam Therapeutics
Via GlobeNewswire
Where Beam Therapeutics Stands With Analysts
Via Benzinga
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals are three CRISPR gene editing stocks you won't want to miss out on. 
Via InvestorPlace
3 Game-Changing Stocks to Buy in March
Innovation is in these companies' DNA. 
Via The Motley Fool
The Top 7 Growth Stocks in Biotech
The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term. 
Via InvestorPlace
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Analyst Ratings for Beam Therapeutics
Via Benzinga
4 Analysts Have This to Say About Beam Therapeutics
Via Benzinga
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Better Buy: Beam Therapeutics or Intellia Therapeutics?
The two clinical-stage gene-editing companies have good long-term prospects. 
Via The Motley Fool
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
From Beam Therapeutics
Via GlobeNewswire
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
Cathie Wood is bullish about these stocks. And so are Wall Street analysts. 
Via The Motley Fool
BMO Capital Upgrades Beam Therapeutics: Here's What You Need To Know
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
5 Top Stocks for February
These growth stocks have more room to run. 
Via The Motley Fool
3 Great Growth Stocks Down 20% or More to Buy Now
These beaten-down stocks could be poised for major rebounds. 
Via The Motley Fool
A New Bull Market Is Coming: 3 Stocks That Could Skyrocket
Aggressive investors should check out these stocks. 
Via The Motley Fool
3 Stocks That Could Create Lasting Generational Wealth
Making money that spans generations requires thinking big. 
Via The Motley Fool
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams. 
Via Benzinga
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
3 Under-the-Radar Biotech Stocks to Buy in 2022
The attraction of all three biotech stocks is their potential. 
Via The Motley Fool
Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside'
Via Benzinga
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.